Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even. Diabet Med. 2013 Sep;30(9):1026-32. doi: Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Ferwana M(1). Introduced in 1999, Actos (pioglitazone) quickly became a best selling. a 40 percent increased risk of bladder cancer over those taking other diabetes drugs. | ||||||
Home | Products | Services | Click Print | Contact Us | What's New | ||||||
|